Articles tagged with Type 1 Diabetes
A new study reveals that glucose fluctuations affect cognitive function in people with Type 1 Diabetes, but individuals differ in their susceptibility. The researchers found that minimizing glucose fluctuations is crucial for optimizing processing speed, especially for older adults and those with certain health conditions.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
The University of Arizona College of Medicine – Tucson has received a $2.7 million grant from the Juvenile Diabetes Research Foundation to test an implantable device that could eliminate the need for glucose testing and insulin injections in people with Type 1 diabetes. The device, developed by Professor Klearchos Papas, uses oxygen-en...
Groundbreaking research reveals changes in pancreatic beta cells at the onset of Type 1 Diabetes, identifying a novel mechanism for protection and a promising therapeutic target in mice and humans. Boosting levels of METTL3 enzyme may slow disease progression.
Healthcare providers must prioritize patient experience to improve diabetes care. This includes explaining treatment options and considering each patient's level of health literacy and cultural background.
A study found that 670 nanometres of red light stimulated energy production within mitochondria, leading to increased glucose consumption and a 27.7% reduction in blood glucose levels. This non-invasive technique has the potential to impact diabetes control by reducing damaging fluctuations of blood glucose.
A multicenter study found that a small pancreas size predicts a faster progression to stage 3 Type 1 diabetes. The study also suggests that using pancreas volume measurement combined with validated metabolic risk measures can more accurately predict disease development than either method alone.
A global study review found negative indirect impacts of the pandemic on people with diabetes, including a rise in non-COVID-19-related deaths, diabetic ketoacidosis among children and adolescents, and sight loss. Pediatric ICU admissions were also significantly increased.
Researchers have developed a new oral insulin medicine that uses nano-carriers to protect insulin from stomach acid, allowing for precise delivery to the liver and reducing the risk of hypoglycemia. This innovation has been successfully tested on baboons, mice, and rats with diabetes, paving the way for human trials starting in 2025.
A new study published in Nature Communications found that AI-driven eye exams can close care gaps among racial and ethnic minority youth with diabetes, populations with historically higher rates of diabetic retinopathy. The technology uses cameras to take pictures of the back of the eye without dilation and provides immediate results.
Researchers have successfully genetically modified pluripotent stem cells to evade immune recognition, offering a viable path forward for pluripotent stem cell-based therapies. The study's findings suggest that these engineered stem cells could pave the way for new treatments for diseases such as Type 1 diabetes and macular degeneration.
A study of 620,000 children found that maternal type 1 diabetes was associated with increased risk for most types of congenital heart defects in offspring. Obesity and overweight were linked to increased risk for complex defects, such as outflow tract obstruction, while decreasing the risk for ventricular septal defects.
A recent study by the Hebrew University proposes a new etiology for early stages of type 1 diabetes, attributing it to disrupted RNA editing within pancreatic beta cells. This perspective challenges long-held beliefs about viral involvement, suggesting potential implications for treatments and cures.
A moderate low-carbohydrate diet has been shown to lower average blood sugar levels and increase time spent within the target glucose range without adverse effects. Participants experienced improved glucose control and felt more satisfied with the new diet.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers at the University of Alberta and Cornell University have developed a device that can secrete insulin under the skin, improving cell survival and diabetes reversal in mice. The innovative approach called SHEATH avoids immunosuppression, making transplants safer for patients with type 1 diabetes.
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
The international consensus report on precision diabetes medicine highlights significant advancements in prevention, diagnosis, treatment, and prognosis. The report also sheds light on knowledge gaps and provides a framework for future research.
Researchers from Cornell and University of Alberta have developed an under-the-skin implant that can secrete insulin without immunosuppression. The approach offers an easier alternative to traditional transplants or insulin injections, with the potential for long-term management of Type I diabetes.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers discover a unique gene, ZNF808, crucial for human pancreas development, contrasting with its absence in other animals. This finding could aid the search for a Type 1 diabetes cure by understanding how humans differ from other species.
Researchers analyzed FDA and patent records to find that manufacturers extended market exclusivity by filing additional patents after FDA approval and obtaining patents on delivery devices. This resulted in a median of 16 years of protection, surpassing other top-selling small-molecule drugs.
Researchers are developing a bioengineered pancreas-like tissue using innovative biomaterials and engineered cells. The goal is to implant these cell-laden scaffolds into patients who need help managing their glucose levels.
A comprehensive review study identifies emerging biomarkers that mirror efforts to halt beta-cell autoimmunity, offering potential applications in clinical practice. The study's findings may improve the management of type 1 diabetes during its partial remission phase.
A team of MSU researchers, supported by a $750,000 grant from JDRF, is creating a new approach to image immune cells in living subjects. This could enable better treatment opportunities and outcomes for patients with Type 1 diabetes, particularly those who are eligible for cell transplantation strategies.
Researchers at the University of Alberta have created a new process to produce insulin-producing pancreatic cells from patient stem cells, achieving a 90% success rate. The breakthrough could lead to injection-free glucose control in people with diabetes and eliminate the need for anti-rejection drugs.
A new Cochrane review has found that human insulin can be stored at room temperature for up to six months without losing potency. This breakthrough research offers hope to millions of people living with diabetes in low- and middle-income countries, particularly those with limited access to refrigeration or healthcare.
A new study provides preliminary evidence that an existing drug, α-difluoromethylornithine (DFMO), could be used to treat type 1 diabetes. The drug has already been FDA-approved for other indications and may offer a more convenient treatment option for patients.
A recent study presents exciting future possibilities for managing type 1 diabetes with the repurposed drug α-difluoromethylornithine (DFMO), which may reduce insulin dependency. The researchers have established preliminary safety of DFMO for individuals with type 1 diabetes, paving the way for innovative therapies.
A new phase 3 clinical trial found that once-weekly basal injection of icodec to treat type 1 diabetes showed non-inferiority to daily insulin degludec in reducing HbA1C levels. However, higher rates of hypoglycaemic episodes were noted in the icodec group.
A new study published in the University of East Anglia shows that automated insulin delivery technology can help pregnant women with type 1 diabetes better manage their blood sugars. The technology, known as Hybrid Closed-Loop or Artificial Pancreas, helps to substantially reduce maternal blood sugars throughout pregnancy.
A new study shows that closed-loop use in type 1 diabetes during pregnancy leads to improved glycemic control and reduced risks. Women using closed-loop technology reported better sleep and fewer worries about their baby's health.
A new study found that hybrid closed-loop technology significantly improved maternal blood sugars in pregnant women with type 1 diabetes. Women who used the technology spent more time within the target range for pregnancy blood sugar levels, gained less weight, and had fewer complications.
A new study published in Diabetologia found that hybrid closed-loop technology improved maternal blood sugars during pregnancy complicated by type 1 diabetes. The technology, which adjusts insulin doses every 10-12 minutes, helped reduce maternal blood sugar levels and weight gain, while also improving baby health outcomes.
The Second International Consensus Report on Precision Diabetes Medicine addresses the need for personalized approaches in diabetes care. The report highlights the potential of precision medicine to improve prevention and treatment outcomes by accounting for disease heterogeneity.
Research suggests that universal screening for type 1 diabetes at two ages could predict most cases of T1D by age 15. Dr. Emily K. Sims emphasizes the importance of identifying individuals with early, presymptomatic stages of disease to prevent life-threatening episodes and improve outcomes.
A phase 1/2 study shows that a stem cell-derived islet therapy has improved blood sugar control in all six adult patients with type 1 diabetes. Three patients achieved insulin independence and showed sustained improvements in blood glucose levels.
A study published in JAMA Network Open found a persistent increase in psychotropic medication dispensation among children and adolescents with type 1 diabetes. The findings highlight the need for integrated pediatric diabetes care and mental health services to detect psychological needs early on.
A recent US study has found that food insecurity significantly increases the risk of severe hypoglycaemia in adults with diabetes. The study, which analyzed data from over 1,000 participants, revealed that those experiencing food insecurity were nearly twice as likely to experience severe hypoglycaemic events.
A study of over 1 million Swedish men found that high blood pressure at age 18 was associated with a higher risk of major cardiovascular events, including heart failure, heart attacks, and strokes. Early intervention for hypertension may be critical to reducing later cardiovascular events.
The study found that type 1 diabetes incidence slightly increased overall, while type 2 diabetes significantly increased after the COVID-19 pandemic. Non-Hispanic Black and Hispanic youth were disproportionately affected.
Researchers have designed an implantable device that carries hundreds of thousands of insulin-producing islet cells and has its own on-board oxygen factory, generating oxygen by splitting water vapor. The device was tested in diabetic mice and maintained normal blood glucose levels for at least a month.
A new study found that islet transplantation significantly reduces the risk of kidney transplant failure and mortality in patients with type 1 diabetes. The study compared the long-term outcomes of patients who received an islet transplantation with those who underwent kidney transplantation and managed their diabetes with insulin alone.
A recent study published in the Journal of Diabetes Science and Technology found that HbA1c levels are markedly higher in young black youth compared to whites with type 1 diabetes. This disparity can lead to increased risk of hypoglycemia and long-term complications if primarily used for insulin management.
Research shows a significant decline in death rates after a first heart attack for individuals without diabetes and those with type 2 diabetes. However, this trend is absent in people with type 1 diabetes. The study suggests that improved standard care following a heart attack may contribute to the observed differences.
A small study found that treating newly diagnosed Type 1 diabetes patients with semaglutide significantly reduced their need for insulin. The medication's ability to stimulate insulin secretion from the beta cells of the pancreas allowed for the elimination of mealtime and basal insulin doses in most patients.
Scientists at CeMM and Max Perutz Labs have reclassified approximately 200 rare immune system disorders using a network-based approach. The study reveals strong similarities between rare diseases and autoimmune conditions, enabling the prediction of treatment efficacy and personalized approaches for diagnosis and treatment.
Researchers found that verapamil prevents the decline of insulin-like growth factor 1 (IGF-1) in Type 1 diabetes patients and promotes IGF-1 signaling in pancreatic beta cells. This mechanism may contribute to the beneficial effects of verapamil on preserving beta-cell function in Type 1 diabetes.
A recent study by Pennington Biomedical Research Center identifies GDF15 as a protein that acts as a cellular signal to enhance insulin secretion. High-intensity exercise training in patients with type 2 diabetes was found to have elevated levels of GDF15, associated with improved glycemic control.
A new study reveals that being divorced is associated with a two-thirds higher risk of lower limb amputation (LLA) in individuals with diabetes compared to those who are married. Additionally, men have a 57% higher risk of LLA than women. The study also found that obesity has a less-than-half the risk of LLA for people with normal weight.
Researchers have identified four metabolism-related biomarkers linked to an increased risk of metastatic prostate cancer in Black men. These biomarkers could lead to improved testing and treatments for this high-risk population, who are more than twice as likely to die from the disease.
Researchers aim to investigate the link between gut microbes and Type 1 diabetes. Emrah Altindis's lab seeks to understand how a protein found in certain bacteria may trigger the onset of T1D.
A recent study found that patients with type 1 diabetes using insulin pumps for extended periods do not exhibit significantly more pathology in their skin compared to short-term users. Despite this, researchers still struggle to understand the underlying causes of skin damage and inflammation at infusion sites.
A $3 million NIH award will support an intervention aimed at improving health outcomes in Black youth with type 1 diabetes. The project aims to optimize family interactions related to diabetes care through mobile health technology, potentially reducing disparities in health outcomes for this vulnerable population.
A Scripps Research study has developed a method to analyze T cells in blood samples to detect early signs of autoimmune disease that could lead to type 1 diabetes. This approach has shown 100% accuracy in identifying at-risk patients and may be used for personalized treatment.
A comprehensive review of biochemical markers for bone fragility in diabetes identifies low bone turnover and alterations in bone quality as key factors. The study suggests that glycemic control, AGEs, and serum IGF-1 may have predictive value for fracture risk in patients with diabetes.
The COVID-19 pandemic has led to a higher incidence of type 1 diabetes and diabetic ketoacidosis in children and adolescents, with increased resources needed for support. Future studies are necessary to assess the trend's persistence and possible underlying mechanisms.
Researchers identify altered proteins predicting islet autoimmunity, a precursor to Type 1 diabetes. The findings mark an important step forward in predicting the disease months before symptoms appear.
Scientists at the University of Bristol have shown that reinforcement learning significantly outperforms commercial blood glucose controllers in terms of safety and effectiveness. The new study improves on prior work by learning from patient records, achieving good blood glucose control through personalized insulin dosing strategies.
Researchers have made progress in generating stem cell-derived beta cells, but current methods are costly and labor-intense. A recent study has found a simple method to address these issues, enhancing maturation and functionality of sBCs.